Live feed08:30:00·10mPRReleasevia QuantisnowU.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette SyndromeByQuantisnow·Wall Street's wire, on your screen.TEVA· Teva Pharmaceutical Industries LimitedHealth Care
